<VariationArchive RecordType="classified" VariationID="13520" VariationName="NM_000297.4(PKD2):c.693dup (p.Ile232fs)" VariationType="Duplication" Accession="VCV000013520" Version="1" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2023-08-06" DateCreated="2017-04-29" MostRecentSubmission="2017-04-29">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="28559" VariationID="13520">
      <GeneList>
        <Gene Symbol="PKD2" FullName="polycystin 2, transient receptor potential cation channel" GeneID="5311" HGNC_ID="HGNC:9009" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>4q22.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="4" Accession="NC_000004.12" start="88007635" stop="88077777" display_start="88007635" display_stop="88077777" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="4" Accession="NC_000004.11" start="88928798" stop="88998930" display_start="88928798" display_stop="88998930" Strand="+" />
          </Location>
          <OMIM>173910</OMIM>
          <Haploinsufficiency last_evaluated="2012-07-06" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=PKD2">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2012-07-06" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=PKD2">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>NM_000297.4(PKD2):c.693dup (p.Ile232fs)</Name>
      <CanonicalSPDI>NC_000004.12:88019554:C:CC</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>4q22.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="4" Accession="NC_000004.12" start="88019554" stop="88019555" display_start="88019554" display_stop="88019555" variantLength="1" positionVCF="88019554" referenceAlleleVCF="T" alternateAlleleVCF="TC" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="4" Accession="NC_000004.11" start="88940706" stop="88940707" display_start="88940706" display_stop="88940707" variantLength="1" positionVCF="88940706" referenceAlleleVCF="T" alternateAlleleVCF="TC" />
      </Location>
      <ProteinChange>I232fs</ProteinChange>
      <HGVSlist>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000297.3" sequenceAccession="NM_000297" sequenceVersion="3" change="c.693dupC">
            <Expression>NM_000297.3:c.693dupC</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000004.11" sequenceAccession="NC_000004" sequenceVersion="11" change="g.88940707dup" Assembly="GRCh37">
            <Expression>NC_000004.11:g.88940707dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000004.12" sequenceAccession="NC_000004" sequenceVersion="12" change="g.88019555dup" Assembly="GRCh38">
            <Expression>NC_000004.12:g.88019555dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_008604.1" sequenceAccession="NG_008604" sequenceVersion="1" change="g.16888dup">
            <Expression>NG_008604.1:g.16888dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000297.4" sequenceAccession="NM_000297" sequenceVersion="4" change="c.693dup" MANESelect="true">
            <Expression>NM_000297.4:c.693dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000288.1" sequenceAccession="NP_000288" sequenceVersion="1" change="p.Ile232fs">
            <Expression>NP_000288.1:p.Ile232fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="non-coding">
          <NucleotideExpression sequenceAccessionVersion="NR_156488.2" sequenceAccession="NR_156488" sequenceVersion="2" change="n.792dup">
            <Expression>NR_156488.2:n.792dup</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001619" Type="non-coding transcript variant" DB="SO" />
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="Allelic variant" ID="173910.0004" DB="OMIM" />
        <XRef Type="rs" ID="1560598042" DB="dbSNP" />
      </XRefList>
      <Comment DataSource="ClinGen" Type="public">ClinGen staff contributed the HGVS expression for this variant.</Comment>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000297.4(PKD2):c.693dup (p.Ile232fs) AND Polycystic kidney disease 2" Accession="RCV000014475" Version="25">
        <ClassifiedConditionList TraitSetID="3718">
          <ClassifiedCondition DB="MedGen" ID="C2751306">Polycystic kidney disease 2</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="1997-06-01" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="1997-06-01" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2017-04-29" MostRecentSubmission="2017-04-29">
        <ReviewStatus>no assertion criteria provided</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">9175744</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="3718" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="6943" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Polycystic kidney disease 2</ElementValue>
                <XRef ID="MONDO:0013131" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">POLYCYSTIC KIDNEY DISEASE 2 WITH OR WITHOUT POLYCYSTIC LIVER DISEASE</ElementValue>
                <XRef Type="MIM" ID="613095" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">POLYCYSTIC KIDNEY DISEASE, ADULT, TYPE II</ElementValue>
                <XRef Type="MIM" ID="613095" DB="OMIM" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">APKD2</ElementValue>
                <XRef Type="MIM" ID="613095" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Preferred">PKD2</ElementValue>
                <XRef Type="MIM" ID="613095" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Autosomal dominant polycystic kidney disease (ADPKD) is generally a late-onset multisystem disorder characterized by bilateral kidney cysts, liver cysts, and an increased risk of intracranial aneurysms. Other manifestations include: cysts in the pancreas, seminal vesicles, and arachnoid membrane; dilatation of the aortic root and dissection of the thoracic aorta; mitral valve prolapse; and abdominal wall hernias. Kidney manifestations include early-onset hypertension, kidney pain, and kidney insufficiency. Approximately 50% of individuals with ADPKD have end-stage kidney disease (ESKD) by age 60 years. The prevalence of liver cysts increases with age and occasionally results in clinically significant severe polycystic liver disease (PLD), most often in females. Overall, the prevalence of intracranial aneurysms is fivefold higher than in the general population and further increased in those with a positive family history of aneurysms or subarachnoid hemorrhage. There is substantial variability in the severity of kidney disease and other extra-kidney manifestations.</Attribute>
                <XRef ID="NBK1246" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301424</ID>
                <ID Source="BookShelf">NBK1246</ID>
              </Citation>
              <XRef ID="C2751306" DB="MedGen" />
              <XRef ID="MONDO:0013131" DB="MONDO" />
              <XRef Type="MIM" ID="613095" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="34726" SubmissionDate="2017-04-26" DateLastUpdated="2017-04-29" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="173910.0004_POLYCYSTIC KIDNEY DISEASE 2" title="PKD2, 1-BP INS, 693C_POLYCYSTIC KIDNEY DISEASE 2" />
        <ClinVarAccession Accession="SCV000034726" DateUpdated="2017-04-29" DateCreated="2013-04-04" Type="SCV" Version="2" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="1997-06-01">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">By systematically screening the entire coding sequence of the PKD2 gene by SSCP analysis and heteroduplex formation in a Cypriot family with polycystic kidney disease (PKD2; 613095), Xenophontos et al. (1997) identified insertion of a cytosine in exon 2 immediately after codon 231. It caused a translation frameshift and was expected to lead to the introduction of 37 novel amino acids before the translation reached a new stop codon. This was the most N-terminal mutation reported to that time, and based on the protein's modeled structure, it was predicted to be within the first transmembrane domain.</Attribute>
              <Citation>
                <ID Source="PubMed">9175744</ID>
              </Citation>
              <XRef DB="OMIM" ID="613095" Type="MIM" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="PKD2" />
          </GeneList>
          <Name>PKD2, 1-BP INS, 693C</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">1-BP INS, 693C</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="173910.0004" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">POLYCYSTIC KIDNEY DISEASE 2</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="34726" TraitType="Disease" MappingType="Name" MappingValue="POLYCYSTIC KIDNEY DISEASE 2" MappingRef="Preferred">
        <MedGen CUI="C2751306" Name="Polycystic kidney disease 2" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

